Guobang Pharma (605507.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 471 million yuan, a year-on-year decrease of 29.67%.

Zhitong Finance APP News, Guobang Pharmaceutical (605507.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 4.589 billion yuan, a year-on-year increase of 2.66%; net profit attributable to the parent company was 471 million yuan, a year-on-year decrease of 29.67%; net profit after deducting non-recurring gains and losses was 447 million yuan, a year-on-year decrease of 27.88%; basic earnings per share were 0.61 yuan.